No title
Background: The C-reactive protein-triglyceride-glucose index (CTI) has been proposed as a novel biomarker for insulin resistance and inflammation. However, its role in the progression trajectory of cardiometabolic multimorbidity (CMM) remains unclear. We aimed to investigate the involvement of the CTI in the CMM progression trajectory. Methods: This prospective study included 266,049 individuals
